Artificial Intelligence: Prostate Cancer Diagnosis Now More Accurate With AI
A team from the Korea Institute of Science and Technology (KIST) uses AI on urine samples to detect prostate cancer.
Current methods detect prostate cancer with only 30% accuracy and require invasive surgery for a final determination through biopsies. This is highly inconvenient and often results in complications such as bleeding and pain. Prostate cancer is the most common cancer in men. (Science Codex)
Researchers at the Korea Institute of Science and Technology (KIST) led by Dr. Kwan Hyi Lee from the Biomaterials Research Center and Professor In Gab Jeong from Asan Medical Center have developed a process that identifies prostate cancer with nearly 100% accuracy. It uses AI and a urine sample, generating a report in merely 20 minutes.
Since the urine-based method is non-invasive, it is very convenient, quick, and inexpensive for patients.
How it works
The team combined an ultra-sensitive, electrical-signal-based biosensor with an AI model. The system measures trace amounts of selected four cancer factors in urine for diagnosing prostate cancer.
The researchers trained the AI model by using the correlation between the four cancer factors, measured by the sensor.
Once trained, the algorithm identified patients with prostate cancer by analyzing complex patterns of the detected signals.
The system detected the presence of prostate cancer in 76 urinary samples with almost 100 percent accuracy.
Reduction in surgery, cost, and medical staff fatigue
“For patients who need surgery and/or treatments, cancer will be diagnosed with high accuracy by utilizing urine to minimize unnecessary biopsy and treatments, which can dramatically reduce medical costs and medical staff’s fatigue,” Professor Jeong at Asan Medical Center said.
“This research developed a smart biosensor that can rapidly diagnose prostate cancer with almost 100 percent accuracy only through a urine test, and it can be further utilized in the precise diagnoses of other cancers using a urine test,” Dr. Lee at the KIST said.
Related Story: An AI Program Identifies Prostate Cancer With Almost 100% Accuracy
Latest Alternative Investment News
Artificial Intelligence: AMD Takes On Rivals In The AI Chip Sweepstakes
Chipmaker AMD (NASDAQ: AMD) has unveiled a range of innovative AI solutions spanning from data centers to personal computers. The AMD Instinct MI300 Series features data center AI accelerators, while…
Digital Assets: Robinhood Debuts Crypto Trading On Its App In The EU
Robinhood (NASDAQ: HOOD) has launched its Crypto app in the European Union (EU), allowing eligible customers to engage in crypto trading with the added incentive of earning Bitcoin rewards. Customers…
FinTech: Samsung Electronics Ties With Mastercard’s Wallet Express
Samsung Electronics (KRX: 005930) and Mastercard (NYSE: MA) have partnered to launch the Wallet Express program, offering banks and card issuers a cost-effective way to expand digital wallet offerings. Through…
Venture Capital: Revaia, Europe’s Biggest Female-Led VC Firm, Racks Up $160M For Second Fund
Revaia, Europe’s largest female-founded venture capital firm, has successfully raised €150 million ($160 million) for its second fund, Revaia Growth II. The funding was secured from sovereign wealth funds, family…